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Cell-free protein expression with bacterial lysates has been demonstrated to produce
soluble proteins in microdroplets. However, droplet assays with expressed membrane
proteins require the presence of a lipid bilayer. A bilayer can be formed in between
lipid-coated aqueous droplets by bringing these into contact by electrokinetic
manipulation in a continuous oil phase, but it is not known whether such interdroplet
bilayers are compatible with high concentrations of biomolecules. In this study, we
have characterized the lifetime and the structural integrity of interdroplet bilayers by
measuring the bilayer current in the presence of three different commercial cell-free
expression mixtures and their individual components. Samples of pure proteins and of
a polymer were included for comparison. It is shown that complete expression
mixtures reduce the bilayer lifetime to several minutes or less, and that this is mainly
due to the lysate fraction itself. The fractiont h a tc o n t a i n st h em o l e c u l e sf o rm e t a b o l i c
energy generation does not reduce the bilayer lifetime but does give rise to current
steps that are indicative of lipid packing defects. Gel electrophoresis conﬁrmed that
proteins are only present at signiﬁcant amounts in the lysate fractions and, when
supplied separately, in the T7 enzyme mixture. Interestingly, it was also found that
pure-protein and pure-polymer solutions perturb the interdroplet bilayer at higher
concentrations; 10% (w/v) polyethylene glycol 8000 (PEG 8000) and 3mM lysozyme
induce large bilayer currents without a reduction in bilayer lifetime, whereas 3mM
albumin causes rapid bilayer failure. It can, therefore, be concluded that the high
protein content of the lysates and the presence of PEG polymer, a typical lysate
supplement, compromise the structural integrity of interdroplet bilayers. However, we
established that the addition of lipid vesicles to the cell-free expression mixture
stabilizes the interdroplet bilayer, allowing the exposure of interdroplet bilayers to
cell-free expression solutions. Given that cell-free expressed membrane proteins can
insert in lipid bilayers, we envisage that microdroplet technology may be extended to
the study of in situ expressed membrane receptors and ion channels. V C 2013
American Institute of Physics.[ http://dx.doi.org/10.1063/1.4791651]
I. INTRODUCTION
Microdroplet technology enables high-throughput compartmentalization and miniaturization
of chemical and biochemical assays as pl-to-ll aqueous volumes contained by a continuous oil
phase.
1–5 One of the most complex droplet-scale reactions demonstrated to date is the expres-
sion of proteins by transcription of a DNA plasmid and subsequent translation of the protein-
encoding RNA by a ribosomal cell extract.
6 The main advantage of this “cell-free” method for
protein production is that there is no requirement for a molecular biology infrastructure,
whereas its main drawback, the high cost of commercial ribosomal extracts, can be offset by
performing the expression in microdroplets. Recent examples include the expression of
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droplets-in-oil.
7,8
Once biomolecules have been enclosed in a droplet compartment, additional reagents can
be supplied by merging the original droplet with a second droplet that carries the desired mol-
ecules.
9 For example, in the case of cell-free protein expression, it can be advantageous to
delay the introduction of the DNA plasmid until the droplet with the ribosomal extract is at a
deﬁned position in an array, or to replenish the molecules that supply metabolic energy after
a certain period of protein expression.
10 Droplet merging with concomitant content mixing is
achieved when two droplets are brought into contact with sufﬁcient force. Although it is chal-
lenging to manipulate the relative position of speciﬁc droplets with conventional ﬂow-driven
microﬂuidics,
11 this can be readily achieved with digital microﬂuidic platforms, where drop-
lets are moved over a two-dimensional array of planar microelectrodes by electrokinetic
forces.
12–14
To prevent spontaneous merging of droplets that are in close proximity, the oil phase is
supplemented with a surfactant that forms a monolayer at the aqueous-oil interface.
15 This
droplet coating is also important because biomolecules can accumulate and unfold at this inter-
face when they are in direct contact with the oil phase.
16–18 A wide range of surfactants are
used in droplet microﬂuidics, including ﬂuorinated surfactants for ﬂuorinated oils,
15 but it is
also possible to employ natural lipids, the main structural component of the cell membrane.
18
Phospholipid molecules assemble at an oil-water interface with their apolar acyl chains in the
oil phase and the polar lipid headgroup in the aqueous phase, thus presenting a biocompatible
membrane-mimicking surface to droplet-enclosed biomolecules. Interestingly, it has been shown
that when two lipid-monolayer coated droplets are brought into contact, the oil between the
droplets is expelled and a lipid bilayer is formed.
19–24 The ability to form interdroplet bilayers
that mimic a cell membrane offers the prospect of extending droplet technology to the study of
membrane proteins, which constitute the target of approximately 50% of all pharmaceutical
drugs.
25
A large number of membrane proteins have been successfully expressed with macroscale
cell-free expression reactions,
26,27 and it has also been demonstrated that the expressed proteins
are incorporated in lipid bilayers, added to the reaction mixture as  50-200nm diameter unila-
mellar liposomes.
28–32 Hence, it can be expected that membrane proteins expressed in a micro-
droplet are able to insert in an interdroplet bilayer, which would open the way to membrane
protein studies, including drug screening, with droplet-based ﬂuorescence efﬂux or electrophysi-
ology assays.
33,34 Bayley and co-workers were indeed able to demonstrate interdroplet bilayer
incorporation of the small potassium ion channel Kcv, directly from the cell-free mixture in
which the protein was expressed. However, they noted that the lifetime of the interdroplet
bilayer, formed by mechanically bringing two droplets into contact with a micromanipulator,
was signiﬁcantly reduced in the presence of the cell-free mixture, resulting in merging of the
two droplets.
35 It should be noted that interdroplet bilayers are generally considered to be more
stable than aperture-suspended bilayers, but lipid bilayers for ion channel electrophysiology
studies are normally not exposed to complex biomolecular mixtures with high protein
concentrations.
36
To explore the potential of microdroplet technology for in situ expressed membrane pro-
teins, we have systematically investigated thes t a b i l i t yo fi n t e r d r o p l e tb i l a y e r sf o r m e db y
electrokinetic manipulation of two droplets on planar microelectrodes—representing a basic
unit of a digital microﬂuidic platform—in the presence of three different commercial cell-free
protein expression mixtures. We have found that interdroplet bilayers are destabilized by
exposure to cell-free reaction mixtures, with bilayer lifetimes of only several minutes or less,
depending on the supplier. The protein-rich lysatef r a c t i o n sa r et h em a i nc o n t r i b u t o r st ot h i s
destabilization, and selected pure proteins and polymers at higher concentrations perturb the
interdroplet bilayer as well. However, the addition of lipid vesicles to the cell-free expression
mixture, especially in combination with a 10-fold dilution of the mixture, stabilizes the inter-
droplet bilayer. This work thus shows that microdroplet technology has the potential to enable
the study of membrane proteins obtained by cell-free expression in interdroplet bilayers.
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A. Chemicals and biochemicals
Asolectin lipid extract from soybean ( 25% phosphatidylcholine), albumin from bovine serum
(BSA), lysozyme from egg white, poly(ethylene glycol) 8000 (PEG 8000), and n-decane ( 99%)
were obtained from Sigma-Aldrich (MO, USA).T h es y n t h e t i cp h o s p h o l i p i d s1 , 2 - d i o l e o y l - sn-glycero-
3-phosphocholine (DOPC) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(10-rac-glycerol) (POPG)
were purchased from Avanti Polar Lipids (AL, USA).
B. Microelectrode array fabrication
Devices were fabricated on 6 in. glass wafers as described by Aghdaei et al.,
21 with minor
modiﬁcations on the photoresist application. Brieﬂy, electrode structures were formed by pat-
terning an evaporated Ti/Pt layer (10/200nm thick) by ion-beam milling. Wafers were diced
into 20 20mm chips and these were cleaned with fuming nitric acid, acetone, and isopropanol
prior to overnight baking at 150  C. A piece of Kapton tape (RS Components, UK) was applied
to protect the contact pads before spin coating of TI Prime adhesion promoter (MicroChem
Corp, MA, USA) at 3000rpm for 20s and baking at 120  C for 2min. Two layers of the nega-
tive photoresist SU8 2000.5 (MicroChem Corp, MA, USA) were then deposited by spin coating
at 6000rpm for 30s, followed by soft-baking at 95  C for 1min. The SU8 was cross-linked by
ﬂood exposure to UV light for 10s at an intensity of 11.85mJ/cm
2, followed by post-exposure
baking at 95  C for 2min, and by hard baking at 150  C for 20min. This procedure produced a
0.5lm thick SU8 ﬁlm, which served as the dielectric that is required for electrokinetic droplet
manipulation on planar electrodes.
12–14 Finally, a plastic reservoir was glued onto the surface of
the microelectrode array to contain the lipid-decane solution. Dimensions of the microelectrodes
and a schematic cross-section of the device layers are shown in Figures 1(j)–1(l).
C. Interdroplet bilayer formation
The microelectrode chip with reservoir (shown in Figure 1(j)) was mounted onto a dual axis
goniometer stage (Thorlabs, NJ, USA) inside a Faraday cage and connected to a signal generator,
the output of which was ampliﬁed using a wideband ampliﬁer and monitored using an oscillo-
scope. The reservoir was ﬁlled with 200ll of either asolectin lipids in decane (20mg/ml) or 1:1
(w/w) DOPC/POPG lipids in decane (4mg/ml). Subsequently, a 2 kHz sinusoidal waveform with
a peak-to-peak intensity of 10V was applied to the two pairs of outer electrodes, (1-10) and
(4-40), shown in Figure 1(k).A2 - ll droplet of sample or of pure buffer solution (150mM KCl,
10mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES buffer), pH 7.4) was placed
inside the two opposing outer electrodes (as described in Aghdaei et al.
21), which then drew the
droplets towards the middle of the electrode array. As the droplets reached the centre of the de-
vice, both pairs of outer electrodes were turned off and the inner electrode pairs (2-20) and (3-30)
were activated by applying 3V at 2kHz. Prior to the droplets making contact, both pairs of outer
electrodes were also activated to hold the droplets stationary, while the hydrated agar-coated tip
of a 250-lm diameter Ag/AgCl electrode, after extensive rinsing with pure buffer solution, was
inserted into each droplet. The outer electrodes were then turned off, allowing the droplets to
gently come into contact. Once contact was made, the applied potential was slowly reduced to
0V and the inner electrodes were turned off.
An Axon Axopatch 200B ampliﬁer and an Axon Digidata 1440A digitizer (Molecular Devi-
ces, CA, USA) were used to take both capacitance and voltage-clamped bilayer current record-
ings using a CV-203BU headstage (Molecular Devices, CA, USA). Current measurements were
obtained with a holding potential of 100mV, a 5kHz low-pass 8-pole Bessel ﬁlter, and a sam-
pling rate of 50kHz. For presentation purposes, the current traces were then digitally ﬁltered
using a 1kHz low-pass ﬁlter. The capacitance was measured by applying a linear voltage ramp
under conditions (triangle waveform; 500Hz frequency, 1 mV peak-to-peak, i.e., 61V/s voltage
ramp), where the measured current response (e.g., 100pA) can be interpreted as the bilayer ca-
pacitance (e.g., 100pF). Prior to measuring a new sample, an interdroplet bilayer was formed
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was measured for 30min. When no current events indicative of bilayer perturbation were
observed and the bilayer did not fail within the 30-min timeframe, the buffer droplets were
removed from the electrode array (i.e., manually guided to the edge of the reservoir) and the
new sample droplet was introduced by pipetting on the array. When this was not the case, which
FIG. 1. Formation (a)–(c), current measurements (d)–(f), and capacitance measurements (g)–(i) of interdroplet lipid
bilayers formed using a planar microelectrode array (j)–(l). The schematic diagrams (a)–(c) depict that (a) aqueous droplets
submerged in a lipid-containing oil phase acquire a lipid monolayer, (b) when two droplets are brought into contact, the oil
between the lipid monolayers is expelled and a lipid bilayer is formed between the droplets, and (c) when an excessive con-
tact force is applied or when the interdroplet bilayer is destabilized by the presence of membrane-perturbing components in
the aqueous phase, the lipid bilayer breaks and the droplets merge into one larger droplet. The electrical characteristics of
this interdroplet bilayer can be measured by placing an electrode in each droplet, and representative current traces (d)–(f)
and capacitance traces (g)–(i) are shown for three different scenarios: (d) and (g) the droplets are in close proximity but
have not yet expelled the interdroplet oil layer, (e) and (h) a defect-free interdroplet bilayer has formed, and (f) and (i) the
interdroplet bilayer has failed during the measurement, resulting in an open circuit and saturation of the ampliﬁer (20nA
cut-off). The insets are an expansion of the region of the main trace marked with an asterisk. Note that bilayer failure is
apparent from both current and capacitance measurements, whereas interdroplet bilayer formation is only conﬁrmed by an
appreciable capacitance value, as calculated from the current response to a triangle-shaped voltage input. The droplets are
brought into contact by electrokinetic forces on a micro-electrode array (j)–(l) as described in Ref. 21: (j) microelectrode
array with oil reservoir, (k) expanded view of the two pairs of outer (1-10 and 4-40) and two pairs of inner (2-20 and 3-30)
electrodes, and (l) schematic cross-section (dashed line in (k)) of the various layers of the device: 1mm glass substrate,
10nm titanium and 200nm platinum electrodes, 500nm SU8 dielectric, and  5mm of oil-lipid solution containing a
 1.5mm diameter aqueous droplet (not to scale).
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niﬁcant concentration, the Ag/AgCl electrodes were recoated with fresh agar and the oil reser-
voir was emptied, washed, and reﬁlled with fresh lipid-oil solution. Electrode re-coating and res-
ervoir cleaning were also performed after every 5-10 experiments, i.e., at least at a daily basis.
D. Cell-free expression mixtures and reference samples
The L1130 E. coli T7 Extract System for Circular DNA (Promega, WI, USA), the
EasyXpress Protein Synthesis Kit (Qiagen Ltd, Crawley, UK), and the Expressway Cell-Free
E. coli Expression System (Invitrogen Life Technologies, CA, USA) were individually prepared
as directed by the manufacturer, with the exception that the RNase-free water was supplemented
with 150mM KCl, 10mM HEPES, pH 7.4, and that no DNA was supplied. It should be noted
that these systems differ in the way the T7 RNA polymerase is supplied: premixed with the S30
lysate in the L1130 and EasyXpress systems, but separately supplied in the Expressway system.
For experiments with speciﬁc fractions of these expression systems, the total amount of the frac-
tion (e.g., the lysate component) was kept constant and the omitted fractions were replaced with
an equal volume of buffer (150mM KCl, 10mM HEPES, pH 7.4). Unilamellar vesicles were
prepared from a dried ﬁlm of DOPC/POPG (1:1, w/w) lipids. The ﬁlm was rehydrated with 1ml
of 150mM KCl, 10mM HEPES, pH 7.4, giving a suspension of multilamellar vesicles. Unila-
mellar vesicles were obtained by passing a freeze-thawed suspension 21 times through a 200nm
polycarbonate ﬁlter in a mini extruder (Avanti Polar Lipids, AL, USA). The vesicles were stored
at 10  C and used within 24h. Polymer and proteins at different concentrations were all prepared
in buffer solution (150mM KCl, 10mM HEPES, pH 7.4).
III. RESULTS AND DISCUSSION
A. Cell-free expression mixtures and specific reaction components
Bilayer capacitance and current measurements, made possible by the insertion of an elec-
trode into each droplet, enable veriﬁcation of interdroplet bilayer formation, estimation of the
bilayer size, and assessment of the integrity of the bilayer (Figures 1(a)–1(i)). For 2-ll droplets
of buffer solution that are brought into contact on the microelectrode array, the initial capaci-
tance is typically 60pF, which increases with time to 150 300pF (Figure 1(h)). Assuming a
speciﬁc bilayer capacitance of 0.5lF/cm
2,
21 this is indicative for the presence of an interdroplet
bilayer with a diameter of 195 276lm. The bilayer current is stable with a peak-to-peak noise
of  6pA after 1kHz ﬁltering, conﬁrming that the bilayer contains no defects (Figure 1(e)).
Lower current noise can be obtained with smaller droplet volumes, which give rise to interdrop-
let bilayers of smaller area with reduced capacitance.
35,37 In our experiments, bilayers formed
from asolectin lipids, a natural lipid mixture extracted from soybean that because of its many
different lipid species could act as an effective matrix for a wide range of membrane proteins,
were stable in the presence of buffer solution. Speciﬁcally, out of 34 independent experiments,
28 bilayers had a lifetime of at least 30min (measurements were terminated after 30min
because these bilayers can have lifetimes of several hours), while the average lifetime of the
six bilayers that failed within this 30-min timeframe was 19min. Bilayers from the synthetic
lipids DOPC and POPG were also stable, with 8 out of 9 independent experiments yielding
bilayers that were still intact after 30min.
Bilayer current recordings with a cell-free expression mixture in one droplet and buffer so-
lution in the second droplet are shown in Figures 2(a)–2(c). It can be seen that the bilayer cur-
rent is elevated, with a current baseline at  5 15pA and with occasional bursts of short-lived
current spikes (<20ms lifetime and up to 80pA amplitude). Similar irregular current bursts or
current steps have also been observed for lipid bilayers in contact with pure buffer solution
when the lipids are near their phase transition temperature
38,39 and for bilayers in the presence
of silica nanospheres,
40,41 and have been attributed to lipid packing defects. Our electrical
recordings thus indicate that the structural integrity of the bilayer is compromised by exposure
to each of the three cell-free expression mixtures. Bilayer rupture, observed as saturation of the
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0.5 1.0nA. Based on eight or more independent experiments, the lifetime of the interdroplet
bilayers of asolectin lipids is on average reduced to 8min in the presence of the L1130 mixture,
and to less than 30s for the EasyXpress and Expressway solutions. Similar observations were
made for the L1130 mixture with DOPC/POPG lipid bilayers (data not shown). Hence, the life-
time of interdroplet bilayers in the presence of cell-free expression mixtures based on S30
lysates
42 is too short to allow experiments with in situ expressed membrane proteins.
To identify the cause of the bilayer instability, which is unlikely to result from an osmotic
imbalance because it is also observed when the mixtures are present in both droplets (data not
shown), we investigated the various components that make up the cell-free protein expression
mixtures (see Table I). It is the S30 cell lysate, extracted from E. coli cell cultures, that con-
tains the actual ribosomal machinery for translation of mRNA.
42–44 This is supplemented with
T7 RNA polymerase for transcription of the user-supplied DNA to mRNA, and with a system
FIG. 2. Interdroplet bilayer current traces for three commercial cell-free reaction mixtures and for selected components.
(a)–(c) Current traces for L1130 (a), EasyXpress (b), and Expressway (c) complete reaction mixtures. (d)–(f) Current traces
for L1130 (d), EasyXpress (e), and Expressway (f) lysate fractions, supplemented with buffer solution. (g)–(i) Current
traces for L1130 (g), EasyXpress (i), and Expressway (j) metabolic energy supply fractions, supplemented with buffer solu-
tion. An abrupt rise in current at the end of a trace indicates bilayer failure (a)–(f); corresponding insets show details of the
current trace immediately before bilayer failure. When the bilayer remains intact for the duration of the experiment (g)–(i),
the insets are an expansion of the region of the main trace marked with an asterisk.
TABLE I. Different fractions of commercial cell-free protein expression kits.
a
L1130 (Promega) T7 S30 extract S30 premix Amino acids
EasyXpress (Qiagen) E. coli extract Reaction buffer
Expressway (Invitrogen) E. coli extract Reaction buffer Amino acids Feed buffer T7 enzyme mix
aThese separately supplied components, named according to the supplier, are to be mixed with a DNA template and supple-
mented with pure water or with a buffer solution to obtain a functional protein expression solution.
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based on pyruvate or creatine kinase enzymes,
10 to sustain the transcription and translation
reactions. Because the various suppliers divide the key biomolecules over these premixed com-
ponent fractions in different ways, we visualized the protein content of these various fractions
by gel electrophoresis. Figure 3 shows that each of the three lysate fractions contains a large
number of <150kDa proteins, which is consistent with previous reports.
45 A band with a mo-
lecular weight corresponding to T7 RNA polymerase is visible for the Expressway enzyme
mix, whereas the remaining component fractions are either devoid of protein or the protein con-
centration is too low to be detected by staining with Coomassie Blue.
To investigate whether the bilayer destabilization by the cell-free mixtures is due to a high
protein concentration, we looked at the effect of the lysate fractions alone. The lysates were
diluted with buffer solution to achieve the same concentration as in the total expression mixture,
and subsequently one 2-ll droplet of diluted lysate was placed in the oil reservoir and brought
into contact with a 2-ll droplet of buffer solution using the electrode array. As shown in Figures
2(d)–2(f), the lysates did not give rise to bursts of bilayer current spikes, but bilayer destabilization
was evident from the decreased bilayer lifetime. In contrast to the total mixtures (Figs. 2(a)–2(c)),
the average lifetime of the lysates by themselves was different for the three suppliers:  3minfor
Expressway lysate,  2min for L1130 lysate and <30s for EasyXpress lysate. The absence of pro-
nounced current spikes and the signiﬁcantly increased bilayer lifetime observed, respectively, with
the L1130 lysate and the Expressway lysate, suggest that it is not just the protein-rich lysate that
contributes to the bilayer destabilization by the complete cell-free expression solutions.
The “energy mixture” fractions, which contain the components for metabolic energy gener-
ation, and sometimes also T7 RNA polymerase (Table I), were also investigated at a dilution
corresponding to the concentrations in the total mixture. The bilayer current traces in Figures
2(g)–2(i) show low-intensity current spikes (up to 30pA) as well as large current steps ( 75pA
amplitude with a lifetime of several seconds), which are not evident for the total cell-free
expression mixtures or for the lysate fractions. Despite these bilayer perturbations, the inter-
droplet bilayer remained intact for 30min for all the three energy mixtures, at which point the
measurement was terminated. It should be noted that the other fractions of the cell-free mix-
tures, such as the amino acids and the T7 RNA polymerase (Table I) did not give rise to any
bilayer perturbations or reduced bilayer lifetimes, and a control experiment with DNA plasmid
also resulted in a bilayer current similar to that observed for pure buffer solution. Hence, both
the lysate and energy-supplying fractions contribute to the bilayer destabilization observed for
FIG. 3. Gel electrophoresis analysis of the protein content of various components of cell-free expression mixtures. The
lanes are loaded as follows: (1) protein ladder with apparent molecular weights in kDa, (2) L1130 lysate, (3) L1130 reaction
buffer, (4) EasyXpress lysate, (5) EasyXpress reaction buffer, (6) Expressway lysate, (7) Expressway reaction buffer,
(8) Expressway T7 enzyme mixture, and (9) protein ladder. The 15% SDS-PAGE gel was run at 150V for 75min in
Tris-glycine buffer and stained with Coomassie Blue.
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cell lysate fractions (Figure 3). It is of interest that the lysates give rise to abrupt bilayer failure
even though the pre-failure current is indicative of a non-perturbed bilayer, while the energy
mixtures, the composition of which is well-deﬁned but proprietary, appear to compromise the
structural integrity of the bilayer but not to the point of bilayer rupture.
B. Pure proteins and polymers
Interdroplet bilayers have been used for a variety of purposes, including formation of drop-
let networks with rectiﬁer properties,
46 characterization of bilayer-embedded ion channels,
21,47
and drug release studies,
48 where the droplets contained only low concentrations of biomole-
cules or proteoliposomes. A notable exception is the work of Bayley and co-workers, who
exposed interdroplet bilayers to a L1130 cell-free mixture with an expressed potassium chan-
nel.
35 Although single-channel activity of this ion channel could be observed, the bilayer was
found to be relatively unstable, which the authors hypothesized to be caused by the presence of
PEG or of residual E. coli lipids in the S30 lysate.
35 To address the inﬂuence of high protein
concentration, PEG polymers, and lipids on the stability of interdroplet bilayers, we investigated
solutions of BSA, lysozyme, and PEG 8000. The addition of lipids is discussed in Sec. IIIC.
Cell-free expression mixtures based on S30 cell lysates contain proteins at a concentration of
 15mg/ml,
49,50 which is estimated to be equivalent to  0.1 1mM. We, therefore, investigated a
positively charged and a negatively charged protein, BSA and lysozyme, respectively, at a con-
centration of 3mM and compared this with the much lower concentrations of 3lM and 3nM,
which is within the typical range for interdroplet bilayer experiments with ion channels such as
a-hemolysin. The current traces for bilayers in between a droplet with a nM protein concentration
and a droplet of pure buffer solution, depicted in Figures 4(a) and 4(c), show a stable baseline as
observed for pure buffer (Fig. 1(e)), and the bilayer remains intact for 30min, after which the
measurement is aborted. Similar results were obtained at a concentration of 3lM (data not
shown). At the higher concentration of 3mM, the two proteins have a different effect on the
bilayer, as shown in Figures 4(b) and 4(d). The negatively charged BSA causes a small number
of current spikes prior to failure of the bilayer, which happens on average after  60s (n 5),
whereas the positively charged lysozyme causes a large number of high-amplitude (up to 1.2nA)
bilayer current spikes, but these do not lead to bilayer failure within the 30-min measurement pe-
riod (n 3). Thus, the effects of a high concentration of BSA and lysozyme are, respectively,
reminiscent of the effect of cell lysates and energy mixtures (Fig. 2). We speculate that the cur-
rent ﬂuctuations observed with lysozyme indicate electrostatic interactions with the overall nega-
tively charged asolectin bilayer, but we cannot explain the rapid bilayer rupture observed for
BSA, although it should be noted that osmotic effects are unlikely to be dominant because the
bilayer lifetime is even shorter when 3mM BSA is present in both droplets (data not shown).
The polymer PEG 8000 is added to cell-free reaction mixtures as a molecular crowding
agent to compensate for the dilution of the pure S30 lysate, typically to a concentration of
4% 5% (w/v).
43,49 We measured the bilayer current in the presence of 0.1% or 10% PEG
8000 on one side of the interdroplet bilayer and pure buffer solution on the other side. As
shown in Figures 4(e) and 4(f), current spikes were observed for both polymer concentrations,
but occurred more frequently, as prolonged current bursts, and with a higher amplitude (up to
800pA) for the higher PEG concentration. However, for both polymer concentrations, the
bilayer would not break within 30min (n 3). Overall, we can conclude that proteins or PEG
at the high concentrations typical for cell-free expression mixtures do destabilize interdroplet
bilayers, either by inducing transient defects manifested as current spikes or by bilayer failure,
which is observed as current saturation and droplet fusion. However, elevated current baselines
following current steps were not observed.
C. Stabilization of interdroplet bilayers
When cell-free expression of membrane proteins would ﬁrst be performed in an isolated
droplet coated with a biocompatible lipid monolayer, this droplet could subsequently be brought
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insertion. To subsequently perform an assay on the bilayer-embedded proteins, for example, a
ﬂuorescence ﬂux experiment or current measurements with putative channel-targeting drugs in
the second droplet,
35 the bilayer is required to be structurally sound and should be stable for at
least 20 30min. We addressed the bilayer stability in the presence of cell-free expression mix-
tures in two ways: dilution of the cell-free mixture and addition of lipid vesicles. The latter
approach also serves to establish whether bilayer destabilization is a result of residual lipid mol-
ecules in the S30 lysates, as discussed above.
The rationale of supplementing the cell-free mixture with lipid vesicles is that additional lipid
surface is provided, effectively lowering the concentration of undesirable membrane-associating
molecules at the interdroplet bilayer. Also, when membrane proteins are expressed by cell-free
expression (e.g., in glass vials), vesicles are commonly added to prevent aggregation of the pro-
duced proteins and to achieve protein incorporation in the vesicle bilayer for subsequent proteoli-
posome assays.
28–32 We supplemented the L1130 cell-free mixture with 0.05, 0.5, or 5lg lipid
(DOPC/POPG 1:1 (w/w)) per ll, which corresponds, respectively, to concentrations of 200-nm
lipid vesicles of 0.2, 2.0, or 20nM. Figures 5(a)–5(c) shows that the dominant features of the
bilayer current in the presence of vesicle-supplemented cell-free expression mixture are current
steps of up to 25pA. Once the current has increased following a current step, the current noise
increases signiﬁcantly and appears as downward spikes, suggesting that there is a tendency for
FIG. 4. Interdroplet bilayer current in the presence of various concentrations of pure proteins and polymers. (a) 3nM bovine
serum albumin; (b) 3mM bovine serum albumin; (c) 3nM lysozyme; (d) 3mM lysozyme; (e) 1% (w/v) poly(ethylene glycol)
8000; (f) 10% (w/v) poly(ethylene glycol) 8000. The insets are an expansion of the region of the main trace marked with an
asterisk. Note that the large current ﬂuctuations observed at the higher polymer (f) and lysozyme (d) concentrations indicate
bilayer instability without bilayer failure, whereas the presence of 3mM albumin (b) causes the bilayer to break within 1min.
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observed in the non-supplemented expression mixtures (Figs. 2(a)–2(c)), but in the presence of
the vesicles, the average lifetime of the bilayer is signiﬁcantly increased, from  2min (see
above) to 22 28min (n 3 for each lipid concentration). This lifetime is sufﬁciently long for
various membrane protein assays, but the observed current steps indicate the bilayer will, to some
extent, be permeable to ions, which can interfere with ion channel experiments.
It is interesting that these relatively well-deﬁned current transitions are observed when lipid
vesicles are added to the cell-free mixture, which could indicate that the current steps in the non-
modiﬁed mixtures are indeed caused by residual E. coli lipids in the S30 cell lysates.
35 We
hypothesize that these steps correspond to the fusion of vesicles with the interdroplet bilayer, with
each vesicle carrying a large number of surface-associated molecules with bilayer perturbing prop-
erties, which gradually diffuse away after a vesicle-bilayer fusion event. In this scenario, increasing
the vesicle concentration would reduce the amount of material associated with each vesicle and
would thus cause less bilayer perturbation, but in our experiments, we could not increase the
amount of lipids while maintaining a homogeneous mixture. Instead, we lowered the concentration
of expression-associated molecules by diluting the L1130 expression mixture 10-fold with buffer
solution. This dilution by itself, without added vesicles, improved the bilayers t a b i l i t ys i g n i ﬁ c a n t l y ,
enabling an average lifetime of 21min (n 6), with only a few brief ( 2ms) elevations in the
baseline (200 400pA) prior to bilayer failure (data not shown). Hence, a 10-fold reduction in the
concentration of all the components of the cell-free mixture mitigates the destabilization effect. In
the presence of 0.2nM vesicles, distinct bilayer current steps with associated elevated bilayer
currents were apparent for the diluted expression mixture, but at higher vesicle concentrations the
current baseline was identical to that observed for pure buffer solution (Figures 5(d)–5(f)), indicat-
ing that the interdroplet bilayer isf r e eo fd e f e c t s ,a n dt h a tt h eb i l a y e r sr e m a i n e di n t a c td u r i n gt h e
30-min measurements. Dilution in combination with vesicle addition, thus, enables a stable inter-
droplet bilayer as a matrix for insertion of cell-free expressed membrane proteins.
IV. CONCLUSIONS
Interdroplet bilayers, and oil-suspended lipid bilayers in general, are typically exposed to
dilute protein or proteoliposome samples.
20,36 This study shows that, when brought into direct
FIG. 5. Interdroplet bilayer current measurements in the presence of non-diluted and diluted L1130 expression mixture,
supplemented with lipid vesicles. (a)–(c) Standard, non-diluted, L1130 mixture with 0.2nM (a), 2.0nM (b), and 20nM
(c) lipid vesicles. (d)–(f) Tenfold diluted L1130 mixture with 0.2nM (a), 2.0nM (b), and 20nM (c) lipid vesicles. The
insets are an expansion of the region of the main trace marked with an asterisk. Dilution in combination with vesicle
addition stabilizes the interdroplet bilayer.
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contains a complex cell-free expression solution. The lifetime of these lipid bilayers is short
(minutes or less), which is attributed to bilayer perturbation by the proteins in the lysate and
energy-supply fractions, but the membranes can be stabilized by the addition of lipid vesicles
to the expression mixture. Moreover, in combination with a 10-fold dilution of the mixture, suf-
ﬁciently stable defect-free bilayers are obtained. Since cell-free expressed membrane proteins
are known to insert into vesicles/liposomes
28–32 and proteoliposome fusion is a means of mem-
brane protein delivery to lipid bilayers,
36,51 we expect our stabilization strategy to be compati-
ble with incorporation of membrane proteins into interdroplet bilayers. Guiding lipid-coated
droplets in digital microﬂuidic platforms
12–14 would enable on-chip initiation and incubation of
protein expression reactions, followed by the formation of interdroplet bilayers by gradually
reducing the distance to droplets that contain reagents for functional assays with bilayer-
incorporated membrane proteins. Further advances in this area could thus extend the manifold
applications of microdroplet technology to the study of membrane receptors and ion channels,
including pharmaceutical drug screening, where the protein-expressing droplet could be sequen-
tially brought into contact with a series of drug-carrying droplets, as demonstrated by Bayley
and co-workers
35 by manual droplet positioning.
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